NAV

16-Bromoepiandrosterone

Identification

Generic Name
16-Bromoepiandrosterone
DrugBank Accession Number
DB05107
Background

16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity in laboratory tests.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 369.336
Monoisotopic: 368.135092819
Chemical Formula
C19H29BrO2
Synonyms
  • 16alpha-bromoepiandrosterone
External IDs
  • HE-2000
  • HE2000
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in cystic fibrosis, HIV infection, hepatitis (viral, B), and malaria.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

HE2000 interacts with certain enzymes, including G6PDH (glucose 6 phosphate dehydrogenase); these enzymes could be involved in the mechanism. Also, the compound is in the steroid hormone series, and involved in control mechanisms in our cells that are much more complex, interacting with receptors and therefore changing the biochemistry of cells. This compound may have many modes of action; we are trying to understand what they may be.

TargetActionsOrganism
UGlucose-6-phosphate 1-dehydrogenaseNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
Beclomethasone dipropionateThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Beclomethasone dipropionate.
BetamethasoneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Betamethasone.
Betamethasone phosphateThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Betamethasone phosphate.
BudesonideThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Budesonide.
CiclesonideThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Ciclesonide.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Immunitin

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Androstane steroids
Direct Parent
Androgens and derivatives
Alternative Parents
Halogenated steroids / 3-beta-hydroxysteroids / 17-oxosteroids / Alpha-haloketones / Secondary alcohols / Cyclic alcohols and derivatives / Organobromides / Organic oxides / Hydrocarbon derivatives / Alkyl bromides
Substituents
16-halo-steroid / 17-oxosteroid / 3-beta-hydroxysteroid / 3-hydroxysteroid / Alcohol / Aliphatic homopolycyclic compound / Alkyl bromide / Alkyl halide / Alpha-haloketone / Androgen-skeleton
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
9735KA370S
CAS number
28507-02-0
InChI Key
CWVMWSZEMZOUPC-JUAXIXHSSA-N
InChI
InChI=1S/C19H29BrO2/c1-18-7-5-12(21)9-11(18)3-4-13-14(18)6-8-19(2)15(13)10-16(20)17(19)22/h11-16,21H,3-10H2,1-2H3/t11-,12-,13+,14-,15-,16+,18-,19-/m0/s1
IUPAC Name
(2R,3aS,3bR,5aS,7S,9aS,9bS,11aS)-2-bromo-7-hydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-one
SMILES
[H][C@@]12C[C@@H](Br)C(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C

References

General References
  1. Frincke JM, Stickney DR, Onizuka-Handa N, Garsd A, Reading C, Krudsood S, Wilairatana P, Looareesuwan S: Reduction of parasite levels in patients with uncomplicated malaria by treatment with HE2000. Am J Trop Med Hyg. 2007 Feb;76(2):232-6. [Article]
  2. Reading C, Dowding C, Schramm B, Garsd A, Onizuka-Handa N, Stickney D, Frincke J: Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000). Clin Microbiol Infect. 2006 Nov;12(11):1082-8. [Article]
  3. Frincke J: HE2000 begins clinical trials: interview with James Frincke, Ph.D. Interview by John S. James. AIDS Treat News. 1999 Jun 4;(No 320):4-7. [Article]
  4. Authors unspecified: HE2000 corrects immune system dysregulation in HIV-positive patients. AIDS Read. 2000 May;10(5):282. [Article]
  5. Authors unspecified: HE2000 shows efficacy. AIDS Patient Care STDS. 1999 Jun;13(6):375. [Article]
PubChem Compound
71613
PubChem Substance
175426947
ChemSpider
64682
BindingDB
50388517
ChEMBL
CHEMBL445472
ZINC
ZINC000003975381

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00209 mg/mLALOGPS
logP4.45ALOGPS
logP4.44Chemaxon
logS-5.2ALOGPS
pKa (Strongest Acidic)18.3Chemaxon
pKa (Strongest Basic)-1.4Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area37.3 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity91.34 m3·mol-1Chemaxon
Polarizability37.98 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9825
Caco-2 permeable+0.8006
P-glycoprotein substrateSubstrate0.5669
P-glycoprotein inhibitor INon-inhibitor0.6611
P-glycoprotein inhibitor IINon-inhibitor0.7795
Renal organic cation transporterNon-inhibitor0.7902
CYP450 2C9 substrateNon-substrate0.8133
CYP450 2D6 substrateNon-substrate0.8886
CYP450 3A4 substrateSubstrate0.7282
CYP450 1A2 substrateNon-inhibitor0.7876
CYP450 2C9 inhibitorNon-inhibitor0.7726
CYP450 2D6 inhibitorNon-inhibitor0.938
CYP450 2C19 inhibitorNon-inhibitor0.9056
CYP450 3A4 inhibitorNon-inhibitor0.7977
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9292
Ames testNon AMES toxic0.8898
CarcinogenicityNon-carcinogens0.9022
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.2317 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9501
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gb9-0009000000-0f5fbf81e06c8ae76575
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0009000000-0c2f341dcf47d3e3cd94
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fvi-0945000000-2e07ddf0047a7832c1f6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0009000000-83132abcb658f92a3969
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-016r-2009000000-e9b1fbf82afbb82b0af6
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0v00-1941000000-c8eaa6a377d290b40354
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-179.20146
predicted
DeepCCS 1.0 (2019)
[M+H]+181.09688
predicted
DeepCCS 1.0 (2019)
[M+Na]+186.87482
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Glucose-6-phosphate 1-dehydrogenase
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis. The main function of this enzyme is ...
Gene Name
G6PD
Uniprot ID
P11413
Uniprot Name
Glucose-6-phosphate 1-dehydrogenase
Molecular Weight
59256.31 Da

Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52